Do you need immunosuppressants if you are experiencing kidney rejection (Acute Renal Rejection)?

From the Guidelines

Yes, immunosuppressants are absolutely necessary if you are rejecting a kidney transplant. When rejection occurs, your immune system is attacking the transplanted kidney, and immunosuppressant medications are required to prevent complete rejection and loss of the organ. The standard immunosuppressive regimen typically includes a combination of medications such as tacrolimus or cyclosporine (calcineurin inhibitors), mycophenolate mofetil, and corticosteroids like prednisone.

During acute rejection episodes, treatment may involve high-dose intravenous methylprednisolone for 3-5 days, possibly followed by anti-thymocyte globulin (ATG) or other antibody therapies if the rejection is severe or resistant to steroids, as suggested by recent guidelines 1. It's critical to take these medications exactly as prescribed and never stop them without medical guidance, as doing so can lead to irreversible rejection. Regular blood tests are necessary to monitor drug levels and kidney function.

Immunosuppressants work by inhibiting various aspects of the immune response that would otherwise attack the foreign tissue, allowing the transplanted kidney to function properly in your body. While these medications have side effects, the benefit of preserving kidney function outweighs these risks in transplant recipients. In fact, a recent review highlights the importance of managing immunosuppression in patients with failing allografts, including those with acute rejection, to prevent sensitization and maintain residual kidney function 1.

Some key points to consider in the management of immunosuppression during acute rejection include:

• Maintaining high levels of immunosuppression during acute management of complications such as acute rejection or graft intolerance syndrome (GIS) 1
• Tapering off mycophenolate mofetil (MMF) while maintaining moderate doses of steroids and calcineurin inhibitors (CNIs) before tapering down 1
• Personalizing the tapering of immunosuppression based on individual patient needs and responses to treatment 1

Overall, the use of immunosuppressants is crucial in preventing rejection and preserving kidney function in transplant recipients, and their management should be guided by recent clinical guidelines and expert recommendations 1.

From the FDA Drug Label

The primary efficacy endpoint was the proportion of patients in each treatment group who experienced treatment failure within the first 6 months after transplantation (defined as biopsy-proven acute rejection on treatment or the occurrence of death, graft loss or early termination from the study for any reason without prior biopsy-proven rejection). Mycophenolate mofetil, when administered with antithymocyte globulin (ATGAM ® †) induction (one study) and with cyclosporine and corticosteroids (all three studies), was compared to the following three therapeutic regimens: (1) antithymocyte globulin (ATGAM ® †) induction/azathioprine/cyclosporine/corticosteroids, (2) azathioprine/cyclosporine/corticosteroids, and (3) cyclosporine/corticosteroids. Mycophenolate mofetil, in combination with corticosteroids and cyclosporine reduced (statistically significant at 0. 05 level) the incidence of treatment failure within the first 6 months following transplantation.

Immunosuppressants are necessary for patients experiencing kidney rejection (Acute Renal Rejection). The use of immunosuppressants such as mycophenolate mofetil, in combination with corticosteroids and cyclosporine, has been shown to reduce the incidence of treatment failure within the first 6 months following transplantation.

• Key points:
  • Mycophenolate mofetil reduces the incidence of treatment failure.
  • Combination therapy with corticosteroids and cyclosporine is effective.
  • Immunosuppressants are necessary for patients with kidney rejection.

2

From the Research

Immunosuppressants in Kidney Rejection

• Immunosuppressants are necessary for preventing acute rejection in kidney transplant patients, with studies showing a significant reduction in acute rejection rates with their use 3, 4.
• The goal of immunosuppression therapy is to optimize allograft and patient survival while minimizing drug toxicity and complications 5.
• Current immunosuppressive protocols typically involve a combination of medications, including calcineurin inhibitors, mycophenolate, and steroids, which provide effective protection against renal allograft rejection 4, 6.

Types of Immunosuppressants

• Calcineurin inhibitors, such as cyclosporine and tacrolimus, are commonly used immunosuppressants that help prevent acute rejection 3, 4.
• Mycophenolate and steroids are also used in combination with calcineurin inhibitors to provide effective immunosuppression 4, 6.
• Alternative immunosuppressants, such as mTOR inhibitors and belatacept, are being developed and may offer improved safety and efficacy 4.

Induction Immunosuppression

• Induction immunosuppression is a critical component of kidney transplant therapy, particularly in high-risk patients 7.
• The use of induction agents, such as polyclonal antibodies and monoclonal antibodies, has been shown to reduce the incidence of acute rejection and improve short-term patient and allograft outcomes 7.